Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 4.3% - Still a Buy?

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) were up 4.3% on Monday . The company traded as high as $19.87 and last traded at $19.68. Approximately 646,996 shares traded hands during trading, a decline of 43% from the average daily volume of 1,134,629 shares. The stock had previously closed at $18.86.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on CAPR shares. Oppenheimer reissued an "outperform" rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Piper Sandler initiated coverage on Capricor Therapeutics in a research note on Monday. They issued an "overweight" rating and a $35.00 price target on the stock. Maxim Group increased their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, September 25th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $8.00 price target on shares of Capricor Therapeutics in a research report on Friday, September 20th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $24.67.

Capricor Therapeutics Stock Up 9.1 %

The firm has a market cap of $657.81 million, a price-to-earnings ratio of -23.20 and a beta of 4.01. The business has a 50 day moving average of $9.04 and a 200 day moving average of $6.52.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The business had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Research analysts predict that Capricor Therapeutics Inc will post -1.13 earnings per share for the current year.

Insider Activity

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of Capricor Therapeutics stock in a transaction on Friday, September 20th. The stock was purchased at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the purchase, the insider now directly owns 7,090,351 shares of the company's stock, valued at approximately $38,004,281.36. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 12.00% of the company's stock.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock valued at $9,274,000 after buying an additional 200,499 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock worth $656,000 after purchasing an additional 84,350 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Capricor Therapeutics during the 2nd quarter worth about $426,000. Bank of New York Mellon Corp boosted its position in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after purchasing an additional 9,040 shares during the period. Finally, Rhumbline Advisers acquired a new position in Capricor Therapeutics in the 2nd quarter valued at $147,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.